Trial reportNeurology2010
Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures.
Trial report in Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES
Evaluation d'un Dispositif de Suivi téléphonique Sur la Qualité de Vie Dans Les Crises Psychogènes Non Epileptiques.
Neuroimaging Biomarker for Seizures
Ketogenic Diet Effects on the Frequency of Non Epileptic Seizures in Patients With Dissociative Neurological Symptom Disorder: a Pilot Study
Controlled Clinical Trial of Transcranial Magnetic Stimulation Versus Conventional Therapy for the Treatment of Functional Neurological Non-Epileptic Seizure Disorder: A Pilot Study
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Personality disorders in individuals with functional seizures: a systematic review.Frontiers in psychiatry · 2024Pooled it
- Outcome measurement in functional neurological disorder: a systematic review and recommendations.Journal of neurology, neurosurgery, and psychiatry · 2020Pooled it
- Sense of control, selective attention, cognitive inhibition, and psychosocial outcomes after Retraining and Control Therapy (ReACT) in pediatric functional seizures.Epilepsy & behavior : E&B · 2023Trial
- Cognitive-behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT.Health technology assessment (Winchester, England) · 2021Trial
- Retraining and control therapy for pediatric psychogenic non-epileptic seizures.Annals of clinical and translational neurology · 2020Trial
- Dissociative symptom trajectories during treatment with selective serotonin reuptake inhibitors for depressive or anxiety disorders.BMC psychiatry · 2026Observational
- Functional neurological disorder: Practical management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Retraining and control therapy: sense of control and catastrophic symptom expectations as targets of a cognitive behavioral treatment for pediatric functional seizures.Frontiers in psychiatry · 2025Article
- Optimizing outcomes when treating functional neurological disorder in acute care settings: case reports depicting the value of diagnostic precision and timely and appropriate psychological interventions using an interdisciplinary framework.Frontiers in psychiatry · 2024Article
- Correspondence: FKBP5 blockade may provide a new horizon for the treatment of stress-associated disorders: An in silico study.Epilepsia open · 2023Article
- Why functional neurological disorder is not feigning or malingering.Nature reviews. Neurology · 2023Review
- Functional Neurological Disorder-Old Problem New Perspective.International journal of environmental research and public health · 2023Review
- Treatment of Psychogenic Nonepileptic Seizures.Current neurology and neuroscience reports · 2022Review
- Article
- Management of Functional Vision Disorders.Current neurology and neuroscience reports · 2022Review
- Functional Neurological Symptom Disorder in Children and Adolescents within Medical Settings.Journal of clinical psychology in medical settings · 2021Review
- Neurostimulation for the treatment of functional neurological disorder: A systematic review.Epilepsy & behavior reports · 2021Review
- Identifying and evaluating novel treatment targets for the development of evidence-based interventions for functional neurological disorder.Epilepsy & behavior reports · 2021Article
- Neuroinflammation as a pathophysiological factor in the development and maintenance of functional seizures: A hypothesis.Epilepsy & behavior reports · 2021Article
- Epidemiology of Functional Seizures Among Adults Treated at a University Hospital.JAMA network open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThere have been few treatment trials for psychogenic nonepileptic seizures (PNES). Some psychotherapies have been shown to improve PNES and comorbid symptom outcomes. We evaluated a pharmacologic intervention to test the hypothesis that sertraline would reduce PNES.
methodsWe conducted a pilot, double-blind, randomized, placebo-controlled trial in an academic medical hospital with epilepsy center outpatients. Subjects aged 18 to 65 years diagnosed with video-EEG-confirmed PNES were treated with flexible-dose sertraline or placebo over 12 weeks. Seizure calendars and symptom scales were charted prospectively. Secondary outcome measures included psychiatric symptom scales and psychosocial variables.
resultsThirty-eight subjects enrolled, and 26 (68%) completed the trial. Thirty-three subjects with nonzero nonepileptic seizure rates at baseline were included in intent-to-treat analysis of the primary outcome. Subjects assigned to the sertraline arm experienced a 45% reduction in seizure rates from baseline to final visit (p = 0.03) vs an 8% increase in placebo (p = 0.78). Secondary outcome scales revealed no significant between-group differences in change scores from baseline to final visit, after adjustment for differences at baseline.
conclusionsPNES were reduced in patients treated with a serotonin selective reuptake inhibitor, whereas those treated with placebo slightly increased. This study provides feasibility data for a larger-scale study. LEVEL OF EVIDENCE: This study provides Class II evidence that flexible-dose sertraline up to a maximum dose of 200 mg is associated with a nonsignificant reduction in PNES rate compared with a placebo control arm (risk ratio 0.51, 95% confidence interval 0.25-1.05, p = 0.29), adjusting for differences at baseline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.